Langerhans cell histiocytosis: Update for the pediatrician

Current Opinion in Pediatrics

Volumn 20, Issue 1, 2008, Pages 23-29

  Weitzman, Sheila ^a   Egeler, R Maarten ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dendritic cell; Langerhans cell histiocytosis; Pediatric; Review

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLADRIBINE; CYTARABINE; INDOMETACIN; MERCAPTOPURINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; STEROID; TACROLIMUS; VINBLASTINE;

AWARENESS; BIOLOGY; BONE; BONE LESION; CAREGIVER; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; DIABETES INSIPIDUS; DIAGNOSTIC PROCEDURE; DRUG MEGADOSE; ENDOCRINE DISEASE; HISTIOCYTOSIS X; HISTOPATHOLOGY; HUMAN; PATHOGENESIS; PEDIATRICIAN; PRIORITY JOURNAL; REVIEW; SEBORRHEA; SKIN MANIFESTATION; STEM CELL TRANSPLANTATION; TARGET CELL;

CHILD; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS;

EID: 38149019315     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e3282f45ba4     Document Type: Review

References (71)

1. Bechan GI, Egeler RM, Arceci RJ. Biology of Langerhans cells and Langerhans cell histiocytosis. Int Rev Cytol 2006; 254:1-43. This article discusses the biology of normal Langerhans cells and LCH cells in detail.
2. Beverley PC, Egeler RM, Arceci RJ, Pritchard J. The Nikolas Symposia and histiocytosis. Nat Rev Cancer 2005; 5:488-494.
3. Grois N, Põtschger U, Prosch H, et al. Risk factors for diabetes insipidus in Langerhans cell histiocytosis. Pediatr Blood Cancer 2006; 46:228-233. This gives a detailed assessment of risk factors for this important complication based on a large number of patients.
4. Haupt R, Nanduri V, Egeler RM. Late effects of Langerhans cell histiocytosis and its association with malignancy. In: Weitzman S, Egeler RM, editors. Histiocytic disorders of children and adults. Cambridge: Cambridge University Press; 2005. pp. 272-292.
5. Lau L, Stuurman K, Weitzman S. Skeletal Langerhans cell histiocytosis in children: permanent consequences and health-related quality of life in long term survivors. Pediatr Blood Cancer 2007 [Epub ahead of print].
6. Mittheisz E, Seidl R, Prayer D, et al. Central nervous system-related permanent consequences in patients with Langerhans cell histiocytosis. Pediatr Blood Cancer 2007; 48:50-60. This article discusses the most important of the potential permanent consequences of LCH in children.
7. Jaffe R. The diagnostic histopathology of Langerhans cell histiocytosis. In: Weitzman S, Egeler RM, editors. Histiocytic disorders of children and adults. Cambridge: Cambridge University Press; 2005. pp. 14-39.
8. Christie LJ, Evans AT, Bray SE, et al. Lesions resembling Langerhans cell histiocytosis in association with other lymphoproliferative disorders: a reactive or neoplastic phenomenon? Hum Pathol 2006; 37:32-39.
9. Romani N, Holzmann S, Tripp CH, et al. Langerhans cells - dendritic cells of the epidermis. APMIS 2003; 111:725-740.
10. Da Costa CE, Annels NE, Faaij CM, et al. Presence of osteoclast-like multi-nucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis. J Exp Med 2005; 201:687-693.
11. Annels NE, Da Costa CET, Prins FA, et al. Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis. J Exp Med 2003; 197:1385-1390.
12. Egeler RM, Favara BE, Van Meurs M, et al. Differential in situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. Blood 1999; 94:4195-4201.
13. Geissmann F, Lepelletier Y, Fraitag S, et al. Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood 2001; 97:1241-1248.
14. Tazi A, Moreau J, Bergeron A, et al. Evidence that Langerhans cells in adult pulmonary Langerhans cell histiocytosis are mature dendritic cells: importance of the cytokine microenvironment. J Immunol 1999; 163:3511-3515.
15. Speziani C, Rivollier A, Gallois A, et al. Murine dendritic cell transdifferentiation into osteoclasts is differentially regulated by innate and adaptive cytokines. Eur J Immunol 2007; 37:747-757.
16. Delprat C. Mechanisms of dendritic cell-derived giant cell formation and LCH. Proceedings of the 23rd Annual Meeting of Histiocyte Society. Cambridge; 2007. p. 14.
17. Willman CL, Busque L, Griffiths BB, et al. Langerhans cell histiocytosis - a clonal proliferation of Langerhans cells. N Engl J Med 1994; 331:154-160.
18. Yu RC, Chu C, Buluwela L, Chu AC. Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet 1994; 343:767-768.
19. Murakami I, Gogusev J, Fournet JC, et al. Detection of molecular cytogenetic aberrations in Langerhans cell histiocytosis of bone. Hum Pathol 2002; 33:555-560.
20. Betts DR, Leibundgut KE, Feldges A, et al. Cytogenetic abnormalities in Langerhans cell histiocytosis. Br J Cancer 1998; 77:552-555.
21. Schouten B, Egeler RM, Leenen PJ, et al. Expression of cell cycle-related gene products in Langerhans cell histiocytosis. J Pediatr Hematol Oncol 2002; 24:727-732.
22. + cells in Langerhans cell histiocytosis reflect the diverse clinical presentation of the disease. J Pathol 2007; 212:188-197.
23. Bechan GI, Meeker AK, De Marzo AM, et al. Telomere length shortening in Langerhans cell histiocytosis. Proceedings of the 23rd Annual Meeting of Histiocyte Society. Cambridge; 2007. p. 34.
24. Glotzbecker MP, Carpentieri DF, Dormans JP. Langerhans cell histiocytosis: clinical presentation, pathogenesis, and treatment from the LCH etiology research group at the Children's Hospital of Philadelphia. Univ Pa Orthop J 2002; 15:67-73.
25. Bernstrand C, Cederlund K, Åhstrom L, Henter J-I. Smoking preceded pulmonary involvement in adults with Langerhans cell histiocytosis diagnosed in childhood. Acta Paediatr 2000; 89:1389-1392.
26. Fernández-Latorre F, Menor-Serrano F, Alonso-Charterina S, Arenas-Jiménez J. Langerhans' cell histiocytosis of the temporal bone in pediatric patients. AJR Am J Roentgenol 2000; 174:217-221.
27. Kamimura M, Kinoshita T, Itoh H, et al. Eosinophilic granuloma of the spine: early spontaneous disappearance of tumor detected on magnetic resonance imaging. J Neurosurg 2000; 93 (2 Suppl):312-316.
28. Guzey FK, Bas NS, Emel E, et al. Polyostotic monosystemic calvarial and spinal Langerhans cell histiocytosis treated by surgery and chemotherapy. Pediatr Neurosurg 2003; 38:206-211.
29. Turgut M, Gurcay O. Multifocal histiocytosis X of bone in two adjacent vertebrae causing paraplegia. Aust N Z J Surg 1992; 62:241-244.
30. Egeler RM, Thompson RC, Voûte PA, Nesbit ME. Intralesional infiltration of corticosteroids in localized Langerhans cell histiocytosis. J Pediatr Orthop 1992; 12:811-814.
31. Munn SE, Olliver L, Broadbent V, Pritchard J. Use of indomethacin in Langerhans cell histiocytosis. Med Pediatr Oncol 1999; 32:247-249.
32. Arceci RJ, Brenner MK, Pritchard J. Controversies and new approaches to treatment of LCH. Hematol Oncol Clin North Am 1998; 12:339-357.
33. Brown RE. Bisphosphonates as antialveolar macrophage therapy in pulmonary Langerhans cell histiocytosis. Med Pediatr Oncol 2001; 36:641-643.
34. Farran RP, Zaretski E, Egeler RM. Treatment of Langerhans cell histiocytosis with Pamidronate. J Pediatr Hematol Oncol 2001; 23:54-56.
35. Kamizono J, Okada Y, Shirahata A, Tanaka Y. Bisphosphonate induces remission of refractory osteolysis in Langerhans cell histiocytosis. J Bone Joint Surg 2002; 17:1926-1928.
36. Kaste SC, Rodriguez-Galindo C, McCarville ME, Shulkin BL. PET-CT in pediatric Langerhans cell histiocytosis. Pediatr Radiol 2007; 37:615-622.
37. Pollono D, Rey G, Latella A, et al. Reactivation and risk of sequelae in Langerhans cell histiocytosis. Pediatr Blood Cancer 2007; 48:696-699.
38. Aricò M, Egeler RM. Clinical aspects of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998; 12:247-258.
39. Koch B. Langerhans cell histiocytosis of temporal bone: role of magnetic resonance imaging. Top Magn Reson Imaging 2000; 11:66-74.
40. Hayes CW, Conway WF, Sundaram M. Misleading aggressive MR imaging appearance of some benign musculoskeletal lesions. Radiographics 1992; 12:1119-1134.
41. Lau L, Krafchik B, Trebo M, Weitzman S. Cutaneous Langerhans cell histiocytosis in children under one year. Pediatr Blood Cancer 2006; 46:66-71. This article contains an important teaching point about skin-only LCH in the newborn and young infant.
42. Munn S, Chu AC. Langerhans cell histiocytosis of the skin. Hematol Oncol Clin North Am 1998; 12:269-286.
43. Kapur P, Erickson C, Rakheja D, et al. Congenital self-healing reticulohistiocytosis (Hashimoto-Pritzker disease): ten-year experience at Dallas Children's Medical Center. J Am Acad Dermatol 2007; 56:290-294.
44. Longaker MA, Frieden IJ, Le Boit PT, Sherertz EF. Congenital 'self-healing' Langerhans cell histiocytosis: the need for long term follow-up. J Am Acad Dermatol 1994; 31:910-916.
45. Esterly NB, Maurer HS, Gonzalez-Crussi F. Histiocytosis-X: a seven-year experience at a children's hospital. J Am Acad Dermatol 1985; 13:481-496.
46. Ladisch S, Gadner H, Aricó M, et al. A randomized trial of etoposide vs vinblastine in disseminated Langerhans cell histiocytosis. Med Pediatr Oncol 1994; 23:107-110.
47. The French LCH Study Group. A multicentre retrospective survey of LCH: 348 cases observed between 1983 and 1993. Arch Dis Child 1996; 75:17-24.
48. Maghnie M, Cosi G, Genovese E, et al. Central diabetes insipidus in children and young adults. N Engl J Med 2000; 343:998-1007.
49. Municchi G, Marconcini S, D'Ambrosio A, et al. Central precocious puberty in multisystem Langerhans cell histiocytosis: a case report. Pediatr Hematol Oncol 2002; 19:273-278.
50. Kaltsas GA, Powles TB, Evanson J, et al. Hypothalamo-pituitary abnormalities in adult patients with Langerhans cell histiocytosis: clinical, endocrinological and radiological features and response to treatment. J Clin Endocr Metab 2000; 85:1370-1376.
51. Maghnie M, Bossi G, Klersy C, et al. Dynamic endocrine testing and magnetic resonance imaging in the long term follow-up of childhood Langerhans cell histiocytosis. J Clin Endocr Metab 1998; 83:3089-3094.
52. Rosenzweig KE, Arceci R, Tarbell NJ. Diabetes insipidus secondary to Langerhans' cell histiocytosis: is radiation therapy indicated? Med Pediatr Oncol 1997; 29:36-40.
53. Dhall G, Finlay JL, Dunkel IJ, et al. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. Pediatr Blood Cancer; 2007 [Epub ahead of print].
54. Pritchard J. Acute ataxia complicating Langerhans cell histiocytosis. Arch Dis Child 2003; 88:178-179.
55. Grois N, Prosch H, Lassmann H, Prayer D. Central nervous system disease in Langerhans cell histiocytosis. In: Weitzman S, Egeler RM, editors. Histiocytic disorders of children and adults. Cambridge: Cambridge University Press; 2005. pp. 208-228.
56. Imashuku S, Okazaki NA, Nakayama M, et al. Treatment of neurodegenerative CNS disease in Langerhans cell histiocytosis with a combination of intravenous gammaglobulin and chemotherapy. Pediatr Blood Cancer; 2007 [E-pub ahead of print].
57. Calming U, Bernstrand C, Mosskin M, et al. Brain 18-FDG PET scan in central nervous system Langerhans cell histiocytosis. J Pediatr 2002; 141:435-440.
58. Grois N, Flucher-Wolfram B, Heitger A, et al. Diabetes insipidus in Langerhans cell histiocytosis: results from the DAL-HX 83 study. Med Pediatr Oncol 1995; 24:248-256.
59. Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr 2001; 138:728-734.
60. Morimoto A, Ikushima S, Kinugawa N, et al. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis. Results from the Japan Langerhans Cell Histiocytosis Study Group-96 Protocol. Cancer 2006; 107:613-619.
61. Minkov M, Grois N, Heitger A, et al. Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator. Med Pediatr Oncol 2002; 39:581-585.
62. Bernard F, Thomas C, Bertrand Y, et al. Multicentre pilot study of 2-chlorodeoxyadenosine and cytosine-arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer 2005; 41:2682-2689.
63. Weitzman S, McClain K, Arceci R. Treatment of relapsed and/or refractory Langerhans cell histiocytosis. In: Weitzman S, Egeler RM, editors. Histiocytic disorders of children and adults. Cambridge: Cambridge University Press; 2005. pp. 254-271.
64. Steiner M, Matthes-Martin S, Attarbaschi A, et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2005; 36:215-225.
65. Kelly M, Kolb M, Bonniaud P, Gauldie J. Re-evaluation of fibrogenic cytokines in lung fibrosis. Curr Pharm Des 2003; 9:39-49.
66. Marti L, Thomas C, Emilé JF, et al. Liver involvement in LCH. The French experience. Proceedings of the XIX Meeting of the Histiocyte Society. Philadelphia; 2003. p. 20.
67. Braier J, Ciocca M, Latella A, et al. Cholestasis, sclerosing cholangitis, and liver transplantation in Langerhans cell histiocytosis. Med Pediatr Oncol 2002; 38:178-182.
68. Tazi A, Hiltermann TJN, Vassallo R. Adult lung histiocytosis. In: Weitzman S, Egeler RM, editors. Histiocytic disorders of children and adults. Cambridge: Cambridge University Press; 2005. pp. 187-207.
69. Soler P, Bergeron A, Kambouchner M, et al. Is high resolution computed tomography a reliable tool to predict the histopathological activity of pulmonary Langerhans cell histiocytosis? Am J Respir Crit Care Med 2000; 162:264-270.
70. Sundar KM, Gosselin MV, Chung HL, Cahill BC. Pulmonary Langerhans cell histiocytosis. Emerging concepts in pathobiology, radiology, and clinical evolution of disease. Chest 2003; 123:1673-1683.
71. Hadzic N, Pritchard J, Webb D, et al. Recurrence of Langerhans cell histiocytosis in the graft after pediatric liver transplantation. Transplantation 2000; 15:815-819.